Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591281 | 1.00 | SIGMAR1 (0.44) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| SCHEMBL6804821 | 0.98 | SIGMAR1 (0.43) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| Hydrochloric Acid SCHEMBL1184615 | 0.98 | SIGMAR1 (0.43) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| SCHEMBL8795419 | 0.98 | SIGMAR1 (0.43) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| SCHEMBL14100024 | 0.98 | SIGMAR1 (0.43) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| SCHEMBL6423835 | 0.96 | SIGMAR1 (0.42) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| Benzene SCHEMBL9148381 | 0.94 | OPRD1 (0.44) | SIGMAR1OPRD1CHRM5CHRM3CHRM2 | |
| SCHEMBL19716571 | 0.92 | SIGMAR1 (0.43) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| SCHEMBL27536506 | 0.86 | SIGMAR1 (0.46) | SIGMAR1OPRD1CHRM5CHRM3CA2 | |
| SCHEMBL6642882 | 0.86 | CHRM5 (0.50) | SIGMAR1OPRD1CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845444-B | Dimethomorph hapten, artificial antigen and antibody, and preparation method and application thereof | 北京勤邦生物技术有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-110845444-A | Dimethomorph hapten, artificial antigen and antibody, and preparation method and application thereof | 北京勤邦生物技术有限公司 | 2020-02-28 | — | — | CN | claimed |
| EP-2455080-A1 | S1P1 receptor agonists for use in the treatment of multiple sclerosis | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | claimed |
| EP-2455081-A1 | S1P1 receptor agonists for use in the treatment of crohn's disease | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | claimed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | claimed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | claimed |
| US-8017104-B2 | diagnostic contrast agent comprising a water dispersible, near-infrared tricarbocyanine, enamine-functionalized dye having a Stoke shift of greater than 50 | CARESTREAM HEALTH, INC. (US) | 2011-09-13 | — | — | US | claimed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | claimed |
| US-20080206886-A1 | Large stoke shift dye used for optical imaging | TROPHY DENTAL INC. | 2008-08-28 | — | — | US | claimed |
| WO-2023140146-A1 | POLISHING COMPOSITION, CONCENTRATED SOLUTION OF POLISHING COMPOSITION, AND POLISHING METHOD | 株式会社フジミインコーポレーテッド | 2023-07-27 | — | — | WO | disclosed |
| CN-116438177-A | Targeted chimeric compounds, pharmaceutical compositions containing same, and preparation methods and uses thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4048667-A1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | Alairion, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-110845444-B | Dimethomorph hapten, artificial antigen and antibody, and preparation method and application thereof | 北京勤邦生物技术有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-105829307-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-0282236-A1 | Process for the preparation of a thiazepine compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-14 | — | — | EP | disclosed |
| US-4758652-A | Process for preparing oligomers and telechels having carboxy-piperazine units, and new oligomers and telechels of poly(carboxypiperazine) | BAYER AG (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0224176-A1 | Process for preparing oligomers and telechelics with carboxy-piperazine units, and oligomers and telechelics of poly(carboxypiperazine) | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0201340-A2 | Toner composition and method for preparing the same | Kao Corporation (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-3993694-A | BACTERICIDE | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | SIGMAR1 96/4885OPRD1 110/4885CHRM5 1041/4885 |
| US-20080206886-A1 | Large stoke shift dye used for optical imaging | ESYT1, SLC7A5, ESYT2 | SIGMAR1 1484/4885OPRD1 3335/4885CHRM5 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.